Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.» Read More
LONDON, May 6- AstraZeneca Plc said on Tuesday it had won U.S. approval for Epanova, a new pill for heart disease, providing a welcome piece of good news as it fights a $106 billion takeover approach from Pfizer Inc..
Pfizer, one of the world's biggest drugs firms, may have had a $106 billion takeover bid for rival AstraZeneca rejected, but analysts expect it to get its way in the end.
A decline in first-quarter profits emphasized Pfizer's need "to do a big deal", says David Williamson, Healthcare Analyst at The Motley Fool.
Raghuram Selvaraju, Head of Healthcare Equity Research at Aegis Capital, discusses Pfizer's motivations behind its takeover bid for U.K.-based AstraZeneca.
NEW YORK, May 5- Pfizer Inc's top officials said on Monday they are weighing all strategies, including potential hostile maneuvers, in the company's effort to seal a $106 billion takeover of British drugmaker AstraZeneca Plc.
Discussing Pfizer's bid for AstraZenaca, and whether his firm will continue to hold its shares, with Sam Isaly of OrbiMed Advisors.
Happy Monday and welcome to the Cinco de Mayo version of the Morning Six-Pack.
May 5- Pfizer Inc reported revenue well below Wall Street expectations on falling sales of generic medicines, underscoring its interest in pursuing a $106 billion bid for rival AstraZeneca to promote new business growth.
Some of the names on the move ahead of the open.
U.S. stock index futures pushed lower on Monday, as shares in Europe fell on concerns about escalating violence in Ukraine.
Pfizer reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals.
May 5- Pfizer Inc, the biggest U.S. drugmaker, on Monday reported revenues well below Wall Street expectations, hurt by falling sales of generic medicines it calls established pharmaceuticals. Pfizer, which is trying to take over Britain's AstraZeneca Plc, earned $2.33 billion, or 36 cents per share, in the first quarter ended March 31.
Britain's opposition Labour party has called for an inquiry into a potential takeover of British firm AstraZeneca by U.S. drugmaker Pfizer.
France's Sanofi and U.S. drugmakers Merck& Co and Abbott Laboratories are exploring selling off their mature drugs that have lost patent protection, Reuters reported this week, citing people familiar with the plans.
LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, opposition Labour party leader Ed Miliband said on Sunday. AstraZeneca rejected a 63 billion pound takeover bid from Pfizer on Friday, but the U.S. firm is expected to pursue its interest.
LONDON, May 4- Britain should conduct an independent assessment of a potential takeover of British pharmaceutical firm AstraZeneca by U.S. drugmaker Pfizer, the leader of the opposition Labour party Ed Miliband said on Sunday.
Employees at Pfizer Inc's U.S. research centers may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
NEW YORK, May 3- Employees at Pfizer Inc's U.S. research centers, such as the La Jolla, California site that specializes in cancer drugs, may want to dust off their resumes if the company's proposed acquisition of Britain's AstraZeneca comes to fruition.
May 3- Pfizer Inc has already had its takeover overtures rebuffed three times by rival AstraZeneca Plc, but investors in the U.S. drugmaker say it can tolerate a little more rejection before going hostile with the deal.
*AstraZeneca rejects Pfizer's raised bid of $106 bln. NEW YORK, May 2- U.S. stocks eased on Friday as an upbeat jobs report was offset by concerns about more violence in Ukraine.